subscribeSubscribe
Clearside Biom Announces Enrollment of Participants in Ph 2b Trial of CLS-AX

Clearside Biom Announces Enrollment of Participants in Ph 2b Trial of CLS-AX
GLOBENEWSWIRE
17 Jul 2023
Share Share
China’s NMPA Accepts sNDA for Frontline Toripalimab & Axitinib in Metastatic RCC

China’s NMPA Accepts sNDA for Frontline Toripalimab & Axitinib in Metastatic RCC
RAPS
12 Jul 2023
Share Share
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX
GLOBENEWSWIRE
01 Jun 2023
Share Share
Clearside Biomedical Announces Plans for ODYSSEY Ph 2b Clinical Trial of CLS-AX

Clearside Biomedical Announces Plans for ODYSSEY Ph 2b Clinical Trial of CLS-AX
GLOBENEWSWIRE
18 Apr 2023
Share Share
Clearside Announces Positive Results from OASIS Extension Study

Clearside Announces Positive Results from OASIS Extension Study
GLOBENEWSWIRE
02 Feb 2023
Share Share
Ocular Announces Interim 7-month Data from U.S. Phase 1 Trial of OTX-TKI

Ocular Announces Interim 7-month Data from U.S. Phase 1 Trial of OTX-TKI
BUSINESSWIRE
27 Sep 2022
Share Share
Amber Specialty Added to Pfizer’s Limited Distribution Network

Amber Specialty Added to Pfizer’s Limited Distribution Network
BUSINESSWIRE
03 Aug 2022
Share Share
Clearside concludes dosing in Phase I/IIa wet AMD trial

Clearside concludes dosing in Phase I/IIa wet AMD trial
CLINICALTRIALSARENA
27 Jul 2022
Share Share
Clearside Biomedical Completes Dosing in OASIS PI/IIa Trial of CLS-AX in Wet AMD

Clearside Biomedical Completes Dosing in OASIS PI/IIa Trial of CLS-AX in Wet AMD
GLOBENEWSWIRE
26 Jul 2022
Share Share
Clearside Biomedical Announces Positive Safety Results from OASIS Ph 1/2a

Clearside Biomedical Announces Positive Safety Results from OASIS Ph 1/2a
GLOBENEWSWIRE
21 Dec 2021
Share Share